Bouthaina Ben Abdallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bouthaina Ben Abdallah has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Amy Hesketh
Bioaster, 69007 Lyon, France
2 shared publications - Benoît Beitz
Bioaster, 69007 Lyon, France
2 shared publications - Cecile Vernochet
Gates Medical Research Institute, Cambridge, MA 02142, USA
2 shared publications - Christophe Védrine
Bioaster, 69007 Lyon, France
2 shared publications - Hélène Laude
Clinical Investigation Center INVOLvE of the Institute Pasteur, 75015 Paris, France
2 shared publications - Janie Parrino
Gates Medical Research Institute, Cambridge, MA 02142, USA
2 shared publications
Latest Publications
- Open Access
- 13 October 2025
- Published by MDPI AG in Applied Microbiology
- Vol. 5 (4) , 110
Bifidobacterium Longum subsp. infantis and Lacticaseibacillus Rhamnosus GG Protect Intestinal Epithelium Against Inflammation-Mediated Damage in an Immunocompetent In-Vitro Model
Impairment of the intestinal epithelial barrier, accompanied by local and systemic inflammation, underlies numerous human pathologies, including inflammatory bowel diseases, celiac disease, sepsis, as well as severe acute malnutrition. Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG (LGG®) have been shown in preclinical studies to strengthen the gut epithelial barrier and attenuate inflammation. This study aimed to compare the ability of four commercial strains of B. infantis, LGG, and their combination to mitigate inflammation-mediated epithelial damage using an in vitro immunocompetent intestinal model. A microfluidic mid-throughput platform OrganoPlate® was used to co-culture intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells (PBMCs). Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide (LPS), and probiotic-conditioned media were applied to the apical side of Caco-2 cells to assess effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics significantly protected the epithelium by modulating tight junction protein expression and promoting transcription of homeostatic cytokines, resulting in a “leak-tight” phenotype. These findings indicate that metabolites produced by B. infantis and/or LGG can protect the intestinal epithelium in vitro, warranting further in vivo studies to evaluate the translational relevance of this effect.
- 13 October 2025
- Published by MDPI AG in Applied Microbiology
- Vol. 5 (4) , 110
Open AccessBifidobacterium Longum subsp. infantis and Lacticaseibacillus Rhamnosus GG Protect Intestinal Epithelium Against Inflammation-Mediated Damage in an Immunocompetent In-Vitro Model
Impairment of the intestinal epithelial barrier, accompanied by local and systemic inflammation, underlies numerous human pathologies, including inflammatory bowel diseases, celiac disease, sepsis, as well as severe acute malnutrition. Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG (LGG®) have been shown in preclinical studies to strengthen the gut epithelial barrier and attenuate inflammation. This study aimed to compare the ability of four commercial strains of B. infantis, LGG, and their combination to mitigate inflammation-mediated epithelial damage using an in vitro immunocompetent intestinal model. A microfluidic mid-throughput platform OrganoPlate® was used to co-culture intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells (PBMCs). Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide (LPS), and probiotic-conditioned media were applied to the apical side of Caco-2 cells to assess effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics significantly protected the epithelium by modulating tight junction protein expression and promoting transcription of homeostatic cytokines, resulting in a “leak-tight” phenotype. These findings indicate that metabolites produced by B. infantis and/or LGG can protect the intestinal epithelium in vitro, warranting further in vivo studies to evaluate the translational relevance of this effect.
- Open Access
- 4 September 2025
- Published by MDPI AG in Preprints.org
Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG Protect Intestinal Epithelium Against Inflammation-Mediated Damage in an Immunocompetent In-Vitro Model
Severe acute malnutrition is associated with enteropathy manifested as disruption of epithelial tight junctions and increased gut permeability, associated with intestinal and systemic inflammation. Bifidobacterium longum subsp. infantis (B. infantis) and Lacticaseibacillus rhamnosus GG (LGG ®, Chr. Hansen A/S) have been shown to strengthen the gut epithelial barrier and to reduce inflammation in preclinical studies. The aim of this study was to compare the ability of four commercial strains of B. infantis, LGG and their combination to mitigate inflammation-mediated epithelial damage using an in-vitro immunocompetent model of the intestine. A microfluidic mid-throughput device OrganoPlate® (Mimetas B.V.) was employed to enable the co-culturing of intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells. Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide and probiotic conditioned media were added to the apical side of the Caco-2 to test the effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics demonstrated significant protection of the epithelium via modulation of tight-junction proteins and homeostatic cytokines gene transcription promoting a “leak-tight” phenotype. These findings demonstrate that B. infantis and/or LGG may have the potential to protect the intestinal epithelium and thus could contribute to alleviating intestinal enteropathy in malnourished children.
- 4 September 2025
- Published by MDPI AG in Preprints.org
Open AccessBifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG Protect Intestinal Epithelium Against Inflammation-Mediated Damage in an Immunocompetent In-Vitro Model
Severe acute malnutrition is associated with enteropathy manifested as disruption of epithelial tight junctions and increased gut permeability, associated with intestinal and systemic inflammation. Bifidobacterium longum subsp. infantis (B. infantis) and Lacticaseibacillus rhamnosus GG (LGG ®, Chr. Hansen A/S) have been shown to strengthen the gut epithelial barrier and to reduce inflammation in preclinical studies. The aim of this study was to compare the ability of four commercial strains of B. infantis, LGG and their combination to mitigate inflammation-mediated epithelial damage using an in-vitro immunocompetent model of the intestine. A microfluidic mid-throughput device OrganoPlate® (Mimetas B.V.) was employed to enable the co-culturing of intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells. Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide and probiotic conditioned media were added to the apical side of the Caco-2 to test the effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics demonstrated significant protection of the epithelium via modulation of tight-junction proteins and homeostatic cytokines gene transcription promoting a “leak-tight” phenotype. These findings demonstrate that B. infantis and/or LGG may have the potential to protect the intestinal epithelium and thus could contribute to alleviating intestinal enteropathy in malnourished children.